Diabetes: Benefits of Early Proactive Treatment in Type 2 Diabetes

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

Say Goodbye to High Blood Sugar Levels & Painful Insulin Shots!

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

The New Nutraceutical Breakthrough To Help You Manage Your Diabetes 

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

Click Here To Learn More!

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

V

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

1 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes 2 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes 3 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes
What Is The Chinese
Secret To Optimum
Blood Pressure?
Why This Is The
Healthiest Oil On Earth?
Click To Learn More
Bring Your Old
Battery Back To Life!
4 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes 5 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes 6 - Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes
How To Survive In
Bed & Nail Women
Like A Rockstar!
100% of Your
Vital Nutrition In
Just 30 Seconds
How A 2000-Year-Old
Nepalese Secret To Cure
Your Sciatica in 7
DAYS OR LESS

Diabetes: Benefits Of Early Proactive Treatment In Type 2 Diabetes

An early proactive approach to type 2 diabetes management may help patients reach their glycemic goals quickly and could reduce excess glycemic burden. It may also prevent or reduce the risk of long-term complications of type 2 diabetes. Current clinical standards often delay treatment adjustments, resulting in patient exposure to an undue glycemic burden, increasing the risk of type 2 diabetes complications.

Evidence has shown that an early approach to type 2 diabetes management can help patients reach and sustain their glycemic goals. The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) agree that while lifestyle optimization and education are essential, minimizing the risks of hypoglycemia and weight gain in type 2 diabetes are priorities.

These groups consider monotherapy (use of one medication) to be appropriate if A1C is less than 7.5% and recommended therapy with a variety of oral agents with caution given to TZDs and sulfonylureas and glinides. Dual therapy was considered appropriate if A1C was between 7.5-9%. Triple therapy with an insulin with or without other agents was recommended for those with A1C greater than 9%. The AACE/ACE algorithm includes major classes of FDA-approved glycemic medications.

However, many studies have shown that currently, a disconnect exists between treatment guidelines and clinical practice. In clinical practice, there is a significant delay in treatment intensification despite poor glycemic control. A conservative incremental treatment approach may lead to prolonged hyperglycemia and a delay in the needed treatment progression. Prolonged hyperglycemic exposure may result in an increased risk of type 2 diabetes complications.

Type 2 diabetes is a complex, progressive disease. Prolonged hyperglycemic exposure may increase the risk of long-term complications, and current conservative clinical practice may lead to an undue glycemic burden for patients. Proactive diabetes management and diligent attainment of glycemic goals through individualization of care should be strongly considered.

Diabetes: Benefits of Early Proactive Treatment in Type 2 Diabetes

An early proactive approach to type 2 diabetes management may help patients reach their glycemic goals quickly and could reduce excess glycemic burden. It may also prevent or reduce the risk of long-term complications of type 2 diabetes. Current clinical standards often delay treatment adjustments, resulting in patient exposure to an undue glycemic burden, increasing the risk of type 2 diabetes complications.

Evidence has shown that an early approach to type 2 diabetes management can help patients reach and sustain their glycemic goals. The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) agree that while lifestyle optimization and education are essential, minimizing the risks of hypoglycemia and weight gain in type 2 diabetes are priorities.

These groups consider monotherapy (use of one medication) to be appropriate if A1C is less than 7.5% and recommended therapy with a variety of oral agents with caution given to TZDs and sulfonylureas and glinides. Dual therapy was considered appropriate if A1C was between 7.5-9%. Triple therapy with an insulin with or without other agents was recommended for those with A1C greater than 9%. The AACE/ACE algorithm includes major classes of FDA-approved glycemic medications.

However, many studies have shown that currently, a disconnect exists between treatment guidelines and clinical practice. In clinical practice, there is a significant delay in treatment intensification despite poor glycemic control. A conservative incremental treatment approach may lead to prolonged hyperglycemia and a delay in the needed treatment progression. Prolonged hyperglycemic exposure may result in an increased risk of type 2 diabetes complications.

Type 2 diabetes is a complex, progressive disease. Prolonged hyperglycemic exposure may increase the risk of long-term complications, and current conservative clinical practice may lead to an undue glycemic burden for patients. Proactive diabetes management and diligent attainment of glycemic goals through individualization of care should be strongly considered.

Leave a Reply

Your email address will not be published. Required fields are marked *